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Abstract
Background: Term Amniotic membrane (AM) is a very attractive source of Mesenchymal Stem Cells (MSCs) due to
the fact that this fetal tissue is usually discarded without ethical conflicts, leading to high efficiency in MSC recovery with
no intrusive procedures. Here we confirmed that term AM, as previously reported in the literature, is an abundant
source of hMSCs; in particular we further investigated the AM differentiation potential by assessing whether these cells
may also be committed to the angiogenic fate. In agreement with the recommendation of the International Society for
Cellular Therapy, the mesenchymal cells herein investigated were named Amniotic Membrane-human Mesenchymal
Stromal Cells (AM-hMSC).
Results: The recovery of hMSCs and their in vitro expansion potential were greater in amniotic membrane than in bone
marrow stroma. At flow cytometry analysis AM-hMSCs showed an immunophenotypical profile, i.e., positive for CD105,
CD73, CD29, CD44, CD166 and negative for CD14, CD34, CD45, consistent with that reported for bone marrow-
derived MSCs. In addition, amniotic membrane-isolated cells underwent in vitro osteogenic (von Kossa stain), adipogenic
(Oil Red-O stain), chondrogenic (collagen type II immunohistochemichal detection) and myogenic (RT-PCR MyoD and
Myogenin expression as well as desmin immunohistochemical detection) differentiation. In angiogenic experiments, a
spontaneous differentiation into endothelial cells was detected by in vitro matrigel assay and this behaviour has been
enhanced through Vascular Endothelial Growth Factor (VEGF) induction. According to these findings, VEGF receptor 1
and 2 (FLT-1 and KDR) were basally expressed in AM-hMSCs and the expression of endothelial-specific markers like
FLT-1 KDR, ICAM-1 increased after exposure to VEGF together with the occurrence of CD34 and von Willebrand
Factor positive cells.
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Conclusion: The current study suggests that AM-hMSCs may emerge as a remarkable tool for the cell therapy of
multiple diseased tissues. AM-hMSCs may potentially assist both bone and cartilage repair, nevertheless, due to their
angiogenic potential, they may also pave the way for novel approaches in the development of tissue-engineered vascular
grafts which are useful when vascularization of ischemic tissues is required.
Background
MSCs are cells with high in vitro expansion potential and
self renewal capacity which were first isolated from bone
marrow [1-3]. Beside their ability to differentiate into
multiple mesoderm-type lineages, e.g. osteoblasts,
chondrocytes and adipocytes, bone marrow derived-
MSCs are also able to differentiate into endothelial cells in
vitro [4]; this opens new possibilities for promoting angio-
genesis through cell-based therapeutic strategies.
Occlusive vascular disease is the most important cause of
death and morbidity in industrialized countries. Treat-
ment of end-stage disease, such as myocardium infarc-
tion, is usually accomplished by angioplasty, surgery,
bypasses and other palliative interventions. However,
patients with occlusive vascular disease develop a promi-
nent collateral vascular network below the occlusive site
through spontaneous arteriogenesis and angiogenesis to
which contribute bone marrow derived-mesenchymal
stem cells (MSCs) [5].
However, considering the invasive procedure related to
this source, there is an increasing interest in investigating
the presence of mesenchymal stem cells with angiogenic
potentiality in adult and fetal tissues as well as in placenta,
umbilical cord blood and vein, Wharton's jelly and amni-
otic membrane [6-9]. Recently human umbilical cord
blood-derived MSC proved to have the ability to differen-
tiate into endothelial cells in vitro [10].
Amniotic membrane is the innermost layer of placenta
and consists of a thin epithelial layer, a thick basement
membrane and an avascular stroma. In the amniotic
membrane two cell types are present of different embryo-
logical origin: amnion epithelial cells derive from embry-
onic ectoderm and amnion mesenchymal cells from
embryonic mesoderm [11,12].
Experimental and clinical studies have demonstrated that
amniotic membrane transplantation promotes re-epithe-
lialisation, decreases inflammation and fibrosis [13] and
modulates angiogenesis [14]. Several growth factors pro-
duced from amniotic membrane are involved in these
processes, such as Transforming Growth Factor-β (TGF-β),
basic Fibroblast Growth Factor (bFGF) [15], Epidermal
Growth Factor (EGF), Transforming Growth Factor-α
(TGFα), Keratinocyte Growth Factor, and Hepatocyte
Growth Factor [16].
Zhang et al. described the presence of mesenchymal stem
cells in human placenta able to differentiate into osteo-
genic, adipogenic and chondrogenic lineages and able to
suppress T-cell proliferation [17]. These results were con-
firmed by Yen et al., who found that placenta-derived
stem cells share Embryonic Stem Cell surface markers
such as SSEA-4, TRA-1-61, TRA-1-80 and are also able to
undergo neurogenic differentiation. The same authors
documented a significantly higher proliferative rate by
placenta-derived cells than by their bone marrow counter-
part [18].
In 't Anker et al. first showed that amniotic membrane
contains a high number of mesenchymal stem cells with
bi-potential osteogenic and adipogenic differentiation
[19]. Moreover Portsmann-Lanz et al. demonstrated that
placental MSCs isolated from the first and third trimester
were able to differentiate into chondrogenic, myogenic
and neurogenic lineages as well, with major differences
among cell types in relation to the different fetal sources
(placenta, chorion and amnios) [20]. The opportunity of
having a fetal tissue that is usually discarded without any
ethical conflict, and the high-yield in stem cell recovery,
makes amniotic membrane a truly exciting alternative
source, and one that reveals new prospects of increasing
the number of clinical applications. Here we characterized
the capability of term amniotic membrane-derived cells to
differentiate towards adipogenic, chondrogenic, osteo-
genic, skeletal myogenic lineages and assessed whether
these cells may encompass the potential for angiogenic
commitment.
In agreement with the recommendation of the Interna-
tional Society for Cellular Therapy, we have named the
mesenchymal cells derived from amnion Amniotic Mem-
brane-human Mesenchymal Stromal Cells (AM-hMSCs)
[21].
Results
Isolation of hMSCs from amniotic membrane
Connective tissue elements, seen in the amniotic mem-
brane sheets by light microscopy (Figure 1A), were
mechanically and enzymatically released.
After three-four weeks of culture a population of homoge-
neous mesenchymal cells was isolated from human amni-
otic membrane and reached confluence. This population
was morphologically indistinguishable from the BM-BMC Developmental Biology 2007, 7:11 http://www.biomedcentral.com/1471-213X/7/11
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hMSC population and was easily expanded in vitro for at
least 15 passages without any visible morphological alter-
ations and with a high percentage of mitotic figures (Fig-
ure 1B).
Moreover the presence of the Oct-4 transcript, coding for
a relevant regulatory protein involved in the maintaining
of stem cell renewal capacity and undifferentiated state in
the embryonic stem cells [22], was revealed through RT-
PCR analysis in AM-hMSCs and the level of expression
was higher than in BM-hMSCs (Figure 2).
The proliferation capacity of MSCs was studied through 2
different assays: first, AM-hMSCs were maintained in a
sub-confluent condition (corresponding to the exponen-
tial phase of growth) in order to determine their expan-
sion capacity (Figure 3A). Second, the proliferation rates
of AM-hMSCs and BM-hMSCs were compared (Figure
3B). As shown in figure 3A, passage three AM-hMSC
expanded approximately 300-fold in 21 days and yielded
2.9 million cells.
Furthermore, at each time point the number of cells in
AM-hMSC cultures was significantly higher than in BM-
hMSCs (Figure 3B).
Immunophenotypical characterization
The immunophenotypical profile of AM-hMSCs was con-
sistent with that reported in the literature for BM-hMSCs.
Thus characterization by flow cytometry revealed that AM-
hMSCs were positive for SH2 (anti-CD105), SH3 and SH4
(anti-CD73), CD29, CD44, CD166, and negative for the
hematopoietic markers CD14, CD34, CD45 (Figure 4).
Differentiation potential
Cells isolated from amniotic membranes were cultured,
under specific conditions for targeted commitments, so as
to differentiate into multiple cell lineages as described in
Methods.
Chondrogenic differentiation was inferred after 3 weeks'
induction by the appearance of abundant extracellular
matrix. Such a conclusion was strengthened by immuno-
histochemical analysis, which showed the presence of
human type II collagen (Figure 5A).
Osteogenic differentiation was revealed as early as the first
week of induction by morphological changes and, at the
end of the induction period, by the formation of mineral-
ized matrix. Cells became flattened and showed calcium
deposits as demonstrated by von Kossa staining, suggest-
ing a close similarity with BM-hMSCs (Figure 5B).
No significant differences were found from the in vitro dif-
ferentiation obtained by BM-hMSCs as described in the
literature and confirmed in our lab (data not shown).
Adipogenic differentiation showed single adipocytic mul-
tivacuolar cells together with small and large colonies, the
size increasing with the time of induction. Large-sized
aggregates displayed an intensive secretion of large neutral
lipid drops which was never observed with BM-hMSC adi-
pogenic differentiation (Figure 5C–H).
No osteogenic, adipogenic or chondrogenic differentia-
tions were seen in the same cells when cultured with the
control medium.
Myogenic differentiation was assessed by RT-PCR for the
myogenic-specific transcription factors MyoD and Myo-
genin. As indicated by Muguruma et al. [23], the presence
of MyoD was investigated after 7 days' culture, while Myo-
genin appeared one week later (Figure 6A). The skeletal
Oct-4 expression Figure 2
Oct-4 expression. RT-PCR analysis of Oct-4 expression in 
5th passage AM-hMSCs and BM-hMSCs. Samples are as fol-
lows: M: Marker; P: Positive control (HeLa cells); BM: BM-
hMSCs; AM: AM-hMSCs; N: Negative control (reagent con-
trol). Beta-actin was used as a house-keeping gene. Amplicon 
lengths: Beta actin 236 bp; Oct-4 249 bp. The data are repre-
sentative of a set of at least three experiments.
Human amniotic membrane Figure 1
Human amniotic membrane. Amniotic membrane sheet 
as seen by light microscopy. The sample has been stained 
with Mallory's stain to highlight the connective tissue ele-
ments (stained red) as indicated by the arrows (A). Morphol-
ogy of AM-hMSCs subconfluent at third passage. 
Magnification ×40. Arrows indicate mitotic figures (B).BMC Developmental Biology 2007, 7:11 http://www.biomedcentral.com/1471-213X/7/11
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protein Desmin was detectable after 3 weeks' induction,
in line with the fact that lineage-specific cytoskeletal fila-
ments are synthesized during late myogenesis. Immuno-
cytochemical staining was used to highlight desmin-
positive cells (Figure 6B,C).
The matrigel assay provided evidence for remarkable fea-
tures concerning the angiogenic potential.
AM-hMSCs cultured with the specific medium and seeded
on top of matrigel (Figures 7A1, B1) showed morpholog-
ical changes after 4 hours (Figures 7A2, B2 ), while capil-
lary-like structures were evident after 20 hours (Figures
7A3, B3). Moreover, cells maintained viability and tube
organization for at least 3 days (data not shown). Unstim-
ulated cells (Figure 7 A3) were able to give rise to capil-
lary-like structures following the same kinetics but with
less organizational efficiency than induced cells (Figure
7B3). Analysis of VEGF receptors expression yielded a
number of interesting observations. First, VEGF receptors
1 and 2 (FLT-1 and KDR) were both found in AM-hMSCs.
Confirming the endothelial differentiation of the cells,
flow cytometry analysis revealed an increased expression
of FLT-1, KDR, ICAM-1 and the appearance of CD34
when cells had been cultured with VEGF (Figure 8). Akin
to these findings, immunofluorescence analysis revealed
that cell treatment with VEGF increased the expression
levels of both VEGF receptors and was associated with a
clear cytoplasmatic granular positivity for von Willebrand
Factor (vWF) as compared with untreated cells (Figure 9).
Discussion
Human mesenchymal stem cells (MSCs) are pluripotent
adult stem cells residing within the bone marrow micro-
environment. MSCs can differentiate not only into oste-
oblasts, chondrocytes, adipocytes, neurons, cardiac
myocytes, but also into vascular endothelial cells. Despite
these appealing properties of bone marrow-derived MSCs,
the cell source may become an issue for a broad clinical
application of cell therapy, because expansion of autolo-
gous bone marrow cells could represent a cumbersome
and low-yield approach. Moreover, recent evidence has
indicated that age and disease state may affect the collec-
tion of sufficient healthy autologous bone marrow for
transplantation [24,25]. Thus, the availability of pluripo-
tent cells that can be implanted without manipulation or
expansion in an allogenic setting would have obvious bio-
medical implications and may hold promise for "off the
shelf" approaches to cell therapy.
In the present study, we directed our attention towards an
alternative source that is easily accessible, high in yield
and ethically acceptable: term amniotic membrane. In
particular, we succeeded in isolating a multipotent stem
cell population that is still of fetal origin and may be supe-
rior in proliferation and differentiation potential to cells
hMSCs Proliferation assay Figure 3
hMSCs Proliferation assay. In vitro expansion of AM-hMSC. Passage three AM-hMSCs were seeded at an initial concentra-
tion of 1000 cells/cm2 (time 0). At day 4, cells were harvested, counted with a hemocytometer and then re-plated at sub-con-
fluent density. The same procedure was repeated at days 7, 10, 14, 17 e 21 (A). Comparison between growth kinetics of 
amniotic membrane derived cells and bone marrow derived cells. The figure shows the mean numbers of hMSCs obtained by 
hemocytometer counting on days 0, 4, 7, 10, 14, 17, 21. At t = 0 1000 cells per cm2 were seeded in 6 well plates. Triplicate cul-
tures were harvested for each point. The values represent the mean and SD of three separate experiments (B).BMC Developmental Biology 2007, 7:11 http://www.biomedcentral.com/1471-213X/7/11
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Immunophenotypical characterization of amniotic membrane derived cells Figure 4
Immunophenotypical characterization of amniotic membrane derived cells. Cells at the 5th culture passage were 
trypsinized, labelled with antibodies against the antigens indicated and analysed by flow cytometry. AM-hMSCs expressed SH2, 
SH3, SH4, CD29, CD44, CD166, while CD45, CD34, CD14 were negative. A representative example of 5 amniotic membrane 
samples is shown.BMC Developmental Biology 2007, 7:11 http://www.biomedcentral.com/1471-213X/7/11
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deriving from adult tissues. Cells were easily isolated
through mechanical and enzymatic digestion and showed
the fibroblast-like morphology usually observed with
mesenchymal stem cells deriving from bone marrow. Fur-
thermore, these cells revealed the characteristic antigen
expression pattern of culture-expanded MSCs, since they
were positive for the common well-defined hMSC mark-
ers [26]. Amniotic membrane is the only source of MSCs
without any contamination from non-fibroblastoid cells,
unlike what has been described for umbilical cord, cord
blood or placenta [18,27,28]. In particular, a variable per-
centage of hematopoietic and endothelial cells is usually
present in cultures of cord blood- or placenta-derived
cells, while such contamination is avoided in the case of
AM-hMSCs, since amniotic membrane supporting con-
nective tissue is truly devoid of any vasculature.
Moreover, the isolation procedure removes epithelial cells
through the first digestion step as demonstrated via mor-
phology analysis by phase-contrast microscopy and in
line with the findings of Bilic et al. who used a similar pro-
tocol [29].
Amniotic membrane has many additional advantages,
since such tissue is usually discarded, yet easily accessible,
and allows a very high recovery of cells. Under our exper-
imental conditions, from day 7 of culture onwards, the
cellular yield of AM-MSCs obtained from a very small area
(about 4 cm2) of amniotic membrane was considerably
higher than the yield obtained from the same number of
bone marrow-derived cells. The number of cells yielded
by the primary culture following our procedure (consider-
ing 4 cm2 of AM) ranged between 1.3 and 1.5 × 106. Con-
sidering the whole area of AM (1300 cm2), ideally the cell
number obtained could be about 4 × 108, a suitable
amount for cell therapy in a human clinical setting [30].
AM-hMSCs expressed the Oct-4 mRNA at higher levels
than BM-hMSCs: this is noteworthy, as the Oct-4 tran-
script is normally found in totipotent embryonic stem
cells and the expression of the gene is downregulated dur-
ing differentiation [22]. The higher level shown by AM-
hMSCs could potentially place these cells in a higher posi-
tion within the stem cell hierarchy compared with MSCs
derived from adult tissues.
AM-hMSCs multi-lineage differentiations in vitro: chondrogenic (A), osteogenic (B), adipogenic (C-H) commitments Figure 5
AM-hMSCs multi-lineage differentiations in vitro: chondrogenic (A), osteogenic (B), adipogenic (C-H) commit-
ments. Chondrogenic differentiation revealed by immunohistochemical stain for collagen II in induced AM-hMSCs. Original 
magnification ×40 (A). Osteogenic differentiation evidenced by the formation of mineralized matrix as shown by von Kossa 
staining. Original magnification ×10 (B).Small colonies with lipid secretion during the first week of adipogenic induction as high-
lighted by Red Oil staining for neutral lipids. Magnification ×4 (C); at higher magnification, multivacuolar adipogenic cells. Mag-
nification ×10 and ×25 respectively (D, E). Big aggregates with intensive and massive lipid secretion at the third week of 
adipogenic induction. Magnification ×10, ×10 and ×40 respectively (F, G, H).BMC Developmental Biology 2007, 7:11 http://www.biomedcentral.com/1471-213X/7/11
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We confirmed the osteogenic and adipogenic differentia-
tion capacity of AM-hMSCs reported by In't Anker et al.
[19]; we also demonstrated that AM-hMSCs are able to
differentiate into chondrogenic lineage. Thus amniotic
membranes may represent a reservoir of multipotent mes-
enchymal stem cells every bit as good as bone marrow,
while other sources that have been investigated have dis-
played only a lower differentiation potential. We found,
for example, that dental pulp-derived mesenchymal stro-
mal cells failed to differentiate towards the chondrogenic
lineage [31].
In adipogenic commitment experiments an unusual
growth pattern of adipocytic colonies was observed. Dur-
ing the first 2 weeks of culture, small colonies were found
and the accumulation of lipid drops was evident. During
the last week of induction, large compact aggregates
secreting abundant amounts of neutral lipids became evi-
dent. To our knowledge, this intensive secretion has never
been described for mesenchymal stem cells deriving from
any sources.
These lipid-secreting aggregates could afford an intriguing
in vitro cell differentiation model for the analysis of adi-
pocytokines. Alterations to such molecules have been
found in some diseases involving both the adipogenic
and the hemopoietic systems [32].
Again, skeletal muscle differentiation has been obtained
with mesenchymal stem cells isolated from lipo-aspirates
and umbilical cord blood [33,34].
We demonstrated that AM-hMSCs are able to differentiate
towards the skeletal myogenic lineage under physiologi-
cal culture conditions without the addition of demethyl-
ating drugs. These results were comparable to those
obtained for human bone marrow-derived multipotent
adult progenitor cells by Muguruma et al [23]. These cells
could be a candidate for the treatment of muscular dystro-
phies, for which corticosteroids still remain the only effec-
tive treatment [35], due to their easily accessible
localization and their high in vitro expansion potential.
Myocardial infarction, peripheral arterial occlusive dis-
ease with critical ischemia, and stroke are the most impor-
tant clinical consequences of end-stage occlusive vascular
disease for which present-day therapies prove inadequate
and treatment remains a palliative.
In this context, the development of a regenerative medi-
cine based on stem cell therapy may hold unprecedented
prospects [36-38].
Classical studies by Asahara et al. demonstrated the exist-
ence of circulating endothelial progenitor cells (EPCs)
within the blood and later their contribution to compen-
satory vessel growth [39]. More recently human bone
marrow-derived and umbilical blood-derived MSCs
revealed the ability to differentiate into the endothelial
cell lineage after having been conditioned with ang-
iogenic growth factors such as VEGF [5,10]. Therefore it is
evident that alternative cell sources for attempting thera-
peutic neovascularization in adults are available but it
should be emphasized that the efficacy of such options
remains to be determined in humans.
Here, we provide evidence for the first time that AM-
hMSCs display angiogenic potential and may therefore
arise as new candidates in cell therapy for vascular dis-
eases. AM-hMSCs spontaneously form capillary-like struc-
tures when cultured in semisolid medium (Matrigel
system). This behaviour was enhanced by exposure to
VEGF, and the endothelial commitment of the cells was
demonstrated by the expression of von Willebrand Factor.
It should be noted that vWF was only expressed in VEGF-
induced cells, so the capillary-like structures formed by
uninduced cells are probably due to the hybrid epithelial-
Skeletal muscle differentiation of AM-hMSCs Figure 6
Skeletal muscle differentiation of AM-hMSCs. RT-PCR 
for skeletal muscle transcription factors MyoD and Myo-
genin. MyoD appears after 1 week of induction while Myo-
genin is expressed in the second week of induction. Samples 
are as follows: lane 1: AM-hMSCs cultured in control 
medium; lane 2: induced AM-hMSCs after 7 days; lane 3: 
induced AM-hMSCs after 14 days; lane 4: positive control 
(RD18 cell line); lane 5: reagent control. Beta-actin was used 
as a house-keeping gene (A). Immunocytochemical staining 
for Desmin after 3 weeks' induction: uninduced AM-hMSCs 
(B) and Desmin positive induced cells (C).BMC Developmental Biology 2007, 7:11 http://www.biomedcentral.com/1471-213X/7/11
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Angiogenic commitment: light microscopic analysis of AM-hMSCs after incubation on Matrigel Figure 7
Angiogenic commitment: light microscopic analysis of AM-hMSCs after incubation on Matrigel. (A) Spontaneous 
organization in capillary-like structures on semisolid medium after 2 (A1), 4 (A2) and 20 (A3) hours of incubation. (B) Increased 
capillary-like structure formation in AM-hMSCs cultured in angiogenic medium supplemented by VEGF 50 ng/mL after 2 (B1), 4 
(B2) and 20 (B3) hours' incubation. Within 4 hours of incubation on semisolid medium, cells preserve a round shape and 
homogeneous distribution (A1 and B1).BMC Developmental Biology 2007, 7:11 http://www.biomedcentral.com/1471-213X/7/11
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mesenchymal ultrastructural phenotype demonstrated in
the amniotic membrane [40]. Another interesting finding
was that AM-hMSCs expressed CD34 and showed
increased expression of FLT-1 and KDR when cultured in
the presence of VEGF: such expression, which recapitu-
lates the basic phenotypic profile of circulating Endothe-
lial Progenitor Cells (EPCs), is further evidence that AM-
hMSCs have an angiogenic potential; the fact that, under
the same culture conditions, AM-hMSCs did not express
the CD133 surface molecule helps to distinguish these
cells from the bone marrow-derived progenitors [41]
(data not shown).
The fact that AM-hMSCs have angiogenic abilities, despite
amniotic membrane being an avascular tissue and
endothelial cells not being present in the original tissue,
raises the issue of whether such an angiogenic potential
could be related to the embryonic origin of the heman-
gioblast. In this respect, it is now evident that in the
mouse embryo even the placenta is a site of hemogenic
endothelium [42]. An additional worthful finding was the
intense expression of ICAM-1 we found following VEGF
stimulation; ICAM-1 is a member of the Ig superfamily
Ca++ dependent transmembrane proteins, whose
increased expression has proved to facilitate leukocyte-
mediated angiogenesis [43]. Furthermore, it has recently
been found that ICAM-1 is critical in driving cell mobility
during angiogenesis [44]; thus it appears that AM-hMSCs
not only have the ability to differentiate into endothelial
cells but also have some inducible properties which are
necessary to regulate angiogenetic processes.
We do not know whether all AM-hMSCs have such ang-
iogenic potential or whether this ability is specific to a
subset of endothelial cell progenitors comprised within
the AM-hMSC primary isolate. The fact that the amniotic
membrane is avascular is against this latter possibility.
Moreover, wide-ranging transcriptional profiling with
Serial Analysis of Gene Expression (SAGE) performed on
single cell-derived colonies of undifferentiated BM-
hMSCs showed that a clonal population of hMSCs is
molecularly heterogeneous, simultaneously expressing
transcripts characteristic of multiple Mesenchymal cell
lineages. These observations provided further evidence for
the stem-like nature of MSCs [45]. We cannot exclude that
these conclusions may also apply to AM-hMSCs. Address-
Endothelial specific markers after AM-hMSCs angiogenic differentiation Figure 8
Endothelial specific markers after AM-hMSCs angiogenic differentiation. Flow cytometry analysis for FLT-1, KDR, 
CD34, ICAM-1, vWF expression in AM-hMSCs cultured in absence and in presence of VEGF (50 ng/ml for 7 days). Uninduced 
cells in black.BMC Developmental Biology 2007, 7:11 http://www.biomedcentral.com/1471-213X/7/11
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ing this issue will require targeted clonogenic studies and
is a subject for our future investigations.
Conclusion
The present observations, focusing on the expansion and
differentiation potential of AM-hMSCs, suggest that this
population may be a remarkable source of pluripotent
cells available for future efforts in cell therapy. BM-hMSCs
may not be the elective choice due to the highly invasive
donation procedure and the decline in MSC number and
differentiation potential with aging. Further studies are
required to fully understand the potential of AM-hMSCs
as a candidate in cell therapy strategies. Their inducible
angiogenic potential may open a new therapeutic
approach, based on tissue-engineered vascular grafts, to
treating various forms of ischemic vascular diseases.
Therapeutic neo-angiogenesis, may be a strategy to restore
tissue damaged because of myocardium infarction,
peripheral occlusive vascular diseases, and other different
arteriopathies.
In order to develop future treatments based on regenera-
tive medicine, it may be worth noticing that the currently
reported yield of AM-hMSCs resulted from a very small
area, which is about 1/325 of the total area of amniotic
membrane. This result, in addition to the fact that both
collagenase and trypsin, which have been used through-
out the initial steps of cell isolation, are currently available
as GMP-grade enzymes, suggests that a remarkable poten-
tial for up-scaling the overall procedure for clinical use
could be envisaged [46,47].
Immunofluorescence detection of vWF, FLT-1 and KDR expression Figure 9
Immunofluorescence detection of vWF, FLT-1 and KDR expression. AM-hMSCs cultured in standard medium for 7 
days did not show vWF expression (A, Magnification ×40). AM-hMSCs stimulated with medium containing 50 ng/ml of VEGF 
for 7 days showed vWF expression (B, Magnification ×40); the immunostaining revealed a cytoplasmatic granular positivity at 
higher magnification (C, Magnification ×100). FLT-1 and KDR expression in induced AM-hMSCs (D, E, Magnification ×40). 
Nuclei are stained with DAPI (blue).BMC Developmental Biology 2007, 7:11 http://www.biomedcentral.com/1471-213X/7/11
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Methods
hMSC isolation and culture
According to the policy approved by the local Ethical
Committee (S.Orsola-Malpighi University Hospital), all
tissue samples were obtained after informed consent.
Term placentas from 6 healthy donor mothers obtained
from caesarean sections were rapidly transferred to the
laboratory, rinsed in Phosphate Buffered Saline (PBS)
containing penicillin and streptomycin (200 U/ml peni-
cillin, 200 μg/ml streptomycin) and used immediately.
Amniotic membrane was separated from chorion through
blunt dissection. Small fragments were utilized for histo-
logical examination. Pieces of amniotic membrane were
minced and subjected to 15-minute digestion with 0.25%
trypsin-EDTA solution. The supernatant was discarded
and the tissue underwent a second digestion with 0.25%
trypsin-EDTA solution, 10 U/ml DNAseI and 0.1% colla-
genase IV solution in DMEM (Dulbecco's modified
Eagle's medium) (all purchased from Sigma-Aldrich Co.,
St. Louis, USA). The fragments were pipetted vigorously
up and down for 5 minutes, avoiding foam; larger pieces
of tissue were allowed to settle under gravity for 5 minutes
at 37°C. Each supernatant was transferred to a fresh tube,
neutralized with Fetal Bovine Serum (FBS, Biochrom, Ber-
lin, Germany), then spun at 1500 rpm for 10 minutes.
Each pellet was re-suspended in 5 ml of culture medium
containing: DMEM, 20% FBS, penicillin 100 U/ml and
streptomycin 100 μg/ml. Cells were seeded in 25 cm2
flasks and the hMSC cultures grew at 37°C in 5% CO2.
Non-adherent cells were removed after 1 week and the
medium (with 10 % of FBS) was subsequently changed
every four days. When the culture reached 90% conflu-
ence, cells were recovered using 0.25% Trypsin-EDTA for
flow cytometric analysis, expansion or other studies.
hMSCs isolated from bone marrow (BM-hMSCs) were
collected from 5 healthy adult volunteers (mean age 45
years; male 3, female 2) in accordance with the protocol
previously described [31].
Flow cytometric analysis
For flow cytometric analysis, the fibroblast-like cells
obtained from amniotic membrane were harvested at the
same point of culture by treatment with 0.25% trypsin-
EDTA and incubated with 1 μg/106 cells FITC-conjugated
antibodies for 40 minutes at 4°C in the dark. The antibod-
ies used were: SH2, SH3 and SH4 kindly provided by Dr.
Mark Pittenger (Osiris Therapeutics, Baltimore, MD,
USA); anti-CD29, anti-CD44 and anti-CD166 (Ancell,
Bayport, MN, USA); anti-CD14, anti-CD34 and anti-
CD45 (Becton Dickinson, San Jose, CA, USA). After wash-
ing, cells were analyzed on a flow cytometer (FACSCali-
bur, Becton Dickinson, San Jose, CA, USA) collecting
10,000 events and the data analyzed by Cell Quest Soft-
ware (Becton Dickinson, San Jose, CA, USA).
Molecular analysis
Total RNA was extracted from 5 × 105 cells (5th passage
BM-hMSCs and AM-hMSCs, HeLa cells as a positive con-
trol) using TRIzol® Reagent according to the manufac-
turer's instructions (Invitrogen, Carlsbad, CA, USA) [48].
Reverse transcription reactions were performed in a 20 μl
volume with 2 μg of total RNA using Cloned AMV First-
Strand cDNA Synthesis Kit® (Invitrogen) following the
manufacturer's protocol. The expression of the following
mRNAs was investigated: Oct-4, Beta actin (control).
Primers used in the RT-PCRs were: 1) Oct-4: annealing
temperature: 60°C, amplicon length 249 bp, sense 5'-
CGT GAA GCT GGA GAA GGA GAA GCT G-3', antisense
5'-CAA GGG CCG CAG CTT ACA CAT GTT C-3'; 2) Beta
actin: annealing temperature: 55°C, amplicon length 236
bp, sense 5'-GGA CTT CGA GCA AGA GAT GG-3', anti-
sense 5'-AGC ACT GTG TTG GCG TAC AG-3'
The PCR products were visualized on a 1,5% agarose gel
stained by ethidium bromide.
Proliferation assay
Passage three AM-hMSCs were seeded at an initial concen-
tration of 1000 cells/cm2 in a 6-well plate. At day 4, cells
were harvested with 0.25% Trypsin-EDTA solution for 3
minutes at 37°C, counted with a hemocytometer and
then re-plated at sub-confluent density. The same proce-
dure was repeated at days 7, 10, 14, 17 e 21.
hMSCs derived from amniotic membrane and from bone
marrow were cultured at 1000 cells/cm2 in duplicate in a
6-well plate. Cells were detached by treatment with
Trypsin-EDTA and counted with a hemocytometer at days
4, 7, 10, 14, 17 e 21 by Trypan blue exclusion (Sigma-
Aldrich Co., St. Louis). Both of these experiments were
performed 3 times for each point described.
In vitro differentiation studies
At the third culture passage, AM-hMSCs were induced to
differentiate into five different types of cell: adipocytes,
osteoblasts, chondroblasts, skeletal muscle cells and
endothelial cells. Differentiation studies were performed
in parallel with BM-hMSCs. (data not shown).
In vitro adipogenic, osteogenic and chondrogenic differen-
tiations were induced following the protocols previously
described [31].
Chondrogenic differentiation of AM-hMSCs
To induce chondrogenic differentiation, aliquots of 5 ×
105 cells were pelleted in polypropylene conical tubes in
0.5 ml of DMEM containing 6.25 μg/ml insulin, 6.25 μg/BMC Developmental Biology 2007, 7:11 http://www.biomedcentral.com/1471-213X/7/11
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ml transferrin, 6.25 μg/ml selenous acid, 5.33 μg/ml lino-
lenic acid, 1.25 mg/ml BSA, 0.35 mM proline, 1 mM
sodium pyruvate, 10-7M dexamethasone, 0.1 mM L-ascor-
bic acid-2-phosphate (all Sigma), supplemented with 10
ng/ml Transforming Growth Factor-β 3 (TGF-β 3 R&D
Systems, Minneapolis, MN, USA). This medium was
replaced every 3–4 days for 3–4 weeks. Pellets were forma-
lin-fixed, embedded in paraffin, examined morphologi-
cally and immunostained for Type II collagen, using
Vectastain elite ABC kit (Vector Laboratories, Burlingame,
CA, USA) (Chemicon Int, Tamecula, CA, USA).
Osteogenic differentiation of AM-hMSCs
To induce osteogenic differentiation, 3 × 103 cells/cm2
were plated in chamber slides (NUNC) in DMEM (Sigma)
supplemented with 10% FBS, 10 mM β-glycerophos-
phate, 0.2 mM ascorbic acid, and 10-8 M dexamethasone
(Sigma), and cultured for 3–4 weeks, replacing the
medium every 2–3 days. To demonstrate osteogenic dif-
ferentiation, the cultures were fixed and von Kossa
stained.
Adipogenic differentiation of AM-hMSCs
To induce adipocyte differentiation, 10 × 103 cells/cm2
were cultured in DMEM supplemented with 10% FBS, 0.5
mM isobutyl-methyl xanthine (IBMX), 200 μM
indomethacin, 10-6M dexamethasone and 10 μg/ml insu-
lin (all Sigma) in chamber slides (NUNC, Naperville, IL,
USA). The cells were cultured, replacing the medium every
2–3 days. After 2–3 weeks of culture the cells contained
neutral lipids in fat vacuoles; they were fixed in 10% for-
malin and stained with fresh oil red-O solution (Sigma).
Myogenic differentiation of AM-hMSCs
In vitro myogenic differentiation was induced according to
the protocol used for human bone marrow-derived
multipotent adult progenitor cells [23]. 5 × 103 cells/cm2
were plated in chamber slides or 25 cm2 flasks in DMEM
supplemented with: 5% of FBS, 40% MCDB-201, ITS-
LA*BSA 100X, 10-8M dexamethasone, 10-4M ascorbic-
acid-2-phosphate, 10 ng/ml bFGF (R&D Systems), 10 ng/
ml Vascular Endothelial Growth Factor (VEGF: Sigma), 10
ng/ml Insulin like Growth Factor-1 (R&D Systems). This
medium was replaced every 3–4 days for 3 weeks. At day
7 and day 14 total RNA was extracted for RT-PCR in order
to investigate the expression of MyoD and myogenin
respectively. Total cellular RNA was extracted by RNeasy
Mini kit (QUIAGEN, Milan, Italy). First strand cDNA was
synthesized with 1 μg of total RNA in a reverse buffer con-
taining 100 pmol of oligo dT, dNTPs 0.25 mM, DTT 10
mM, 20 U of Rnase Inhibitor and 50 U of M-MuLV RT.
The mixture was incubated for 1 hour at 42°C, heated for
5 minutes at 94°C and stored at -20°C until used. PCR
amplifications were carried out in a thermal cycler with
cDNA derived from 200 ng of total RNA, reaction buffer
10×, MgCl2 2 mM, dNTP 0.2 mM, primers 0.2 mM and
1.25 U of Taq DNA polymerase. Primers were designed
and synthesized for Myo-D (sense 5'-AAG CGC CAT CTC
TTG AGG TA-3'; antisense 5'-GCG CCT TTA TTT TGA TCA
CC-3') (Invitrogen, Milan, Italy) and Myogenin (sense 5'-
AGG CTC AAG AAG GTG AAT GAG G-3'; antisense 5'-
AGG TTG TGG GCA TCT GTA GGG T-3'). Myogenin prim-
ers were kindly provided by Prof Carla De Giovanni (sec-
tion of Cancer Research, Department of Experimental
Pathology, University of Bologna, Italy) [49]. Each cycle
included a denaturation step (95°C for 1 min), an anneal-
ing step (60°C for 1 min) and an extension step (72°C for
1 min). The PCR products were visualized on a 2% agar-
ose gel stained by ethidium bromide.
A cell line deriving from rhabdomyosarcomas (RD18)
was used as a positive control for skeletal myogenic mark-
ers.
After 3 weeks' induction AM-hMSCs were fixed with Ace-
ton:Methanol = 7:3 and analysed by immunocytochemis-
try assay in order to investigate the presence of desmin
protein. In particular a Vectastain elite ABC kit (Vector
Laboratories) was used with primary anti-Desmin anti-
body (Sigma).
Angiogenic differentiation
Confluent cells were cultured in DMEM with 2%FBS and
50 ng/ml VEGF for 7 days, changing the medium every 2
days [4]. AM-hMSCs cultured in DMEM with 10% FBS for
the whole induction period were considered the negative
control.
Analysis of capillary formation was performed using
Matrigel (Becton Dickinson and Co, Franklin Lakes, New
Jersey, USA). 50 μl of gel matrix solution was applied to
each well on a 96-well plate and incubated for 1 hour at
37°C. 1 × 104 cells were suspended in 50 μl of DMEM,
plated onto the gel matrix and incubated at 37°C. Capil-
lary-like structures were observed by optical microscopy
after 2, 4 and 20 hours and at regular intervals during the
following 3 days.
In order to evaluate the FLT-1, KDR and von Willebrand
Factor (vWF) expression, AM-hMSCs cultured as above
described were harvested, counted and seeded on cover
slips in 6-well plates at a concentration of 5000 cells/cm2.
Cells were allowed to adhere overnight, then immunoflu-
orescence stain was performed as briefly described. Cells
were washed with PBS and fixed with 2% paraformalde-
hyde for 4 minutes at room temperature. For intracyto-
plasmatic protein staining (vWF), 1% triton X-100 was
added during the fixation. Aspecific antibody binding
sites were blocked by incubating with 1% bovine serum
albumin for 1 hour at 37°C. After blocking cells wereBMC Developmental Biology 2007, 7:11 http://www.biomedcentral.com/1471-213X/7/11
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labelled for 45 minutes at 37°C in the presence of a
mouse monoclonal antibody (dilution of 1:50) directed
against vWF (DakoCytomation, Denmark), a goat poly-
clonal antibody (diluition of 1:50) direct against FLT-1
(Santa Cruz Biotechnology-USA), a mouse monoclonal
antibody (diluition of 1:50) directed against KDR (Sig-
maAldrich, Italy). Excess primary antibody was removed
by six washes with PBS and the cells were stained at 37°C
for 45 minutes with a rabbit fluorescein-conjugated anti
mouse IgG (DakoCytomation, Denmark) and with a don-
key fluorescein-conjugated anti-goat IgG (Santa Cruz Bio-
technology, USA). Nuclei were labelled by adding a drop
of Pro Gold Antifade with DAPI (InvitrogenMolecular
Probes, Italy).
Cells adhering onto cover slips were observed and photo-
graphed under a microscope (Axiovert 40 Zeiss, Ger-
many) with UV lamp.
The AM-hMSCs from the same angiogenic experiment
were analyzed, in parallel assays, by flow cytometry using
the following antibodies according to the manufactorers'
suggestions: FLT-1 (Santa Cruz Biotechnology-USA), KDR
(RD System, Minneapolis, USA), CD34 (Beckman-Coul-
ter, Miami, USA), ICAM-1 (Beckman-Coulter, Miami,
USA) and vWF (DakoCytomation, Denmark). In order to
reveal vWF, the cells were permeabilized with the Intrapep
Kit (Beckman-Coulter), incubated with vWF MoAb and
subsequently incubated with secondary anti-mouse IgG
FITC (DakoCytomation-Denmark).
Data were acquired using a Cytomics FC500 Flow Cytom-
eter equipped with two sources (Beckman-Coulter).
Results were analyzed using the CXP Software (Beckman-
Coulter).
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